GLP-1 medication

The GLP-1 Pill Is Here. What It Means for Weight Management.

Oral semaglutide changes the conversation about GLP-1 treatment, but tablets are not automatically simpler. A physician explains what patients need to know.

Élan Clinic · Educational article · Published May 22, 2026

For the past few years, GLP-1 receptor agonists, the class of medications that includes semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), have quietly transformed how medicine thinks about obesity. Not as a willpower problem. Not as a lifestyle failure. As a chronic disease with effective, physician-managed treatments.

Until recently, those treatments came in one form: an injection, once a week. That changed in early 2026, when the U.S. Food and Drug Administration approved an oral formulation of semaglutide specifically for weight management, the first GLP-1 pill approved for obesity. Eli Lilly's fully oral GLP-1 candidate, orforglipron, is expected to follow in Q2 2026 pending FDA approval.

The pill era has arrived. Here is what you need to know.

Why the Injection Was the Only Option, Until Now

GLP-1 medications mimic a hormone your gut releases after eating. They suppress appetite, slow gastric emptying, and signal to the brain that you are full. The problem is that GLP-1 is a peptide, a chain of amino acids, and peptides are destroyed by stomach acid before they reach the bloodstream. That is why, for years, these drugs had to be injected: it was the only reliable way to deliver them.

Oral semaglutide already existed as Rybelsus, a pill used for type 2 diabetes management. But the doses were low, and the formulation was not optimised for significant weight loss. The new oral Wegovy uses a higher-dose version of the same absorption technology, a compound called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), that temporarily protects semaglutide from stomach acid and allows it to be absorbed through the stomach lining.

Orforglipron, Lilly's candidate, takes a different approach entirely: it is a small molecule (not a peptide at all), which means it is absorbed conventionally and does not require special formulation tricks. Phase 3 trial data has now been published, and the results are clinically meaningful.

Does the Pill Work as Well as the Injection?

This is the question every patient asks first. The honest answer: the injectable formulations currently have the stronger evidence base, but the gap is narrowing fast.

The pivotal STEP 1 trial, published in the New England Journal of Medicine in 2021 (Wilding et al.), showed that once-weekly injectable semaglutide produced an average weight loss of approximately 15% of body weight over 68 weeks in people with obesity without diabetes. The SURMOUNT-1 trial for tirzepatide (Mounjaro), published in NEJM in 2022 (Jastreboff et al.), pushed that further, approximately 21% weight loss at the highest dose (15 mg) over 72 weeks.

Phase 3 data for oral semaglutide in obesity is still being published, and head-to-head comparisons with the injectable form are ongoing. For orforglipron, Phase 3 results are now in. The ATTAIN-1 trial, published in the New England Journal of Medicine and presented at the EASD Annual Meeting in 2025, showed an average weight loss of 12.4% (approximately 12.4 kg) at the highest dose (36 mg) over 72 weeks in adults with obesity but without diabetes. The ATTAIN-2 trial, reported in August 2025, extended these findings to patients with type 2 diabetes, who lost an average of 10.5% of body weight (22.9 lbs), with an average reduction in HbA1c of 1.8%. A third trial, ATTAIN-MAINTAIN, confirmed that the weight loss achieved can be sustained. Across all three trials, the safety profile was consistent with that of injectable GLP-1 medications. Following the completion of ATTAIN-2, Lilly initiated global regulatory submissions.

What the numbers also confirm: these are not one-time treatments. When semaglutide is stopped, most of the weight comes back. The STEP 1 extension study (Wilding et al., Diabetes, Obesity and Metabolism, 2022) found that approximately two-thirds of weight lost was regained within 12 months of discontinuation. Weight management is a long-term commitment, whether your medication is injectable or oral.

Side Effects: What Changes With the Pill?

The side effect profile of oral semaglutide is broadly similar to the injectable form: nausea, vomiting, and digestive discomfort are the most common complaints, especially in the early weeks of treatment. These typically improve as the body adjusts.

There is one practical difference. The oral pill must be taken correctly to work, on an empty stomach, with no more than 120 ml of plain water, at least 30 minutes before any food, drink, or other medication. For some patients, that morning routine is easy to maintain. For others, it is genuinely difficult. Your physician needs to know which category you fall into before prescribing.

One concern that has circulated online, a possible link between GLP-1 medications and suicidal ideation, has been examined in a large pharmacoepidemiological study. Sodhi et al. (Nature Medicine, 2024; n = 107,910) found the opposite: semaglutide was associated with a 49-73% lower risk of suicidal ideation compared to other diabetes and weight management medications. This should not be taken as a blanket reassurance, patients with psychiatric history still require careful monitoring, but the data do not support the fear.

Availability in Estonia: What to Expect

Oral Wegovy has received FDA approval in the United States. European Medicines Agency (EMA) review is the next step before it becomes available in EU countries, including Estonia. Regulatory timelines vary, but EU approval typically follows FDA approval within 12-18 months for high-priority medications.

In the meantime, injectable Wegovy and Mounjaro are both available in Estonia. The European Association for the Study of Obesity (EASO) endorses GLP-1 receptor agonists as a primary pharmacotherapy option for obesity, recommended as part of a comprehensive treatment programme that includes lifestyle intervention, not as a replacement for it. It is a significant shift in clinical guidelines, and one that aligns with the evidence.

Orforglipron, with Phase 3 trials now complete and global regulatory submissions initiated by Lilly, is expected to receive FDA approval as early as Q2 2026. EU market entry is anticipated in late 2026 or 2027, pending EMA review. We are watching the regulatory timeline closely.

What This Means for Élan Patients

At Élan Clinic, our approach has never been to prescribe and step back. Effective weight management requires a physician who monitors your progress, adjusts your treatment as your needs change, and helps you build the habits that make the medication work, and that protect you when treatment eventually tapers.

The arrival of oral GLP-1 options expands what we can offer. Some patients are excellent candidates for the injectable form, greater efficacy data, established protocols, predictable absorption behaviour. Others will do better with a pill: patients who have needle anxiety, patients who travel frequently, or those whose routines make weekly injections impractical.

We do not have a preferred answer. We have a preferred process: a thorough assessment, an honest conversation about the evidence, and a treatment plan built around you, not around whichever medication is trending.

If you have questions about oral GLP-1 medications, orforglipron, or whether your current programme should be reviewed in light of the new options, book a consultation. That is what we are here for.

Dr. Ingmar Lindström is a specialist in physician-led weight management at Élan Clinic, Tallinn (Sepapaja 12/1). For appointments: +372 52 99939 or elanclinic.ee.

Editorial notes (internal, remove before publishing):

v2 changes (2026-03-17):

If you are considering GLP-1 treatment or changing your current plan, book a medical consultation with Élan Clinic. We will assess indications, risks, monitoring needs, and a realistic maintenance plan.